Caitlin Fierheller, PhDPostdoctoral Research Fellow in Women’s Precision Prevention Email: c.fierheller@qmul.ac.ukProfileResearchPublicationsProfileI joined the Women’s Precision Prevention (WPP) team with Prof Ranjit Manchanda as a postdoctoral research associate in February 2023. I am currently working across clinical trials in the WPP team which focus on population-based genetic testing, targeted screening, cancer prevention (including surgical) and health economics. I am a co-investigator on the PROTECT-C (Population based germline testing for early detection and prevention of cancer) and DETECT-2 (Direct to patient testing at cancer diagnosis for precision prevention-2). I also work on the Jewish Hereditary Cancer Review, PRESCORES (Preventing Endometrial Cancers: Comparing Risk-Reducing Strategies), PROTECTOR (Prevention ovarian cancer through early excision of tubes and late ovarian removal), and other studies. I completed my PhD in Human Genetics at McGill University, Montreal, Canada in 2023. My research focused on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer. I obtained my BSc in 2016 in Genetics and Biochemistry from Western University, London, Canada.ResearchResearch Interests:Cancer prevention Cancer genetics Population-based genetic testingPublications Wei X, Sun L, Slade E et al. (2024). Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. nameOfConference DOI: 10.1001/jamanetworkopen.2023.55324 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/94579 Wei X, Sun L, Slade E et al. (2023). EE675 Cost-Effectiveness Analysis of Cancer Susceptibility Gene-Specific Prevention and Surveillance Strategies for Ovarian and Breast Cancer. nameOfConference DOI: 10.1016/j.jval.2023.09.940 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/93539 Sobocan M, Chandrasekaran D, Sideris M et al. (2023). Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. nameOfConference DOI: 10.1111/1471-0528.17675 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91563 Alenezi WM, Fierheller CT, Serruya C et al. (publicationYear). Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. nameOfConference DOI: 10.3389/fonc.2023.1111191 QMRO: qmroHref Fierheller CT, Alenezi WM, Serruya C et al. (publicationYear). Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. nameOfConference DOI: 10.3390/genes14020277 QMRO: qmroHref Alenezi WM, Milano L, Fierheller CT et al. (publicationYear). The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. nameOfConference DOI: 10.3390/cancers14092251 QMRO: qmroHref Alenezi WM, Fierheller CT, Revil T et al. (publicationYear). Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants. nameOfConference DOI: 10.3390/genes13040697 QMRO: qmroHref Fierheller CT, Guitton-Sert L, Alenezi WM et al. (2021). A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. nameOfConference DOI: 10.1186/s13073-021-00998-5 QMRO: qmroHref Fierheller CT, Alenezi WM, Tonin PN (publicationYear). The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. nameOfConference DOI: 10.3390/cancers13143406 QMRO: qmroHref Alenezi WM, Fierheller CT, Recio N et al. (publicationYear). Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. nameOfConference DOI: 10.3390/genes11080856 QMRO: qmroHref